Letter: The Q425R Variant in Chronic Hepatitis Delta—Distinguishing Cirrhosis Prevalence From Portal Hypertension Severity
Alimentary Pharmacology & Therapeutics · 2026-10-03
DOI: 10.1111/apt.71030 ↗At a glance
Leserbrief in Alimentary Pharmacology & Therapeutics, published online on 2026-10-03. Written by Dandan Weng and 1 co-authors. Institution: Department of Infectious Diseases, Affiliated Yangming Hospital of Ningbo University, Yuyao, Zhejiang, China. Cited 1 times so far (Crossref); 6 references.
Abstract (original language)
Není k dispozici žádný abstrakt.
Authors and institutions
- Department of Infectious Diseases, Affiliated Yangming Hospital of Ningbo University, Yuyao, Zhejiang, China.
ORCID profiles: Dandan Weng
Cite
APA
Weng, D., & Zhang, P. (2026). Letter: The Q425R Variant in Chronic Hepatitis Delta—Distinguishing Cirrhosis Prevalence From Portal Hypertension Severity. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.71030
Vancouver
Weng D, Zhang P. Letter: The Q425R Variant in Chronic Hepatitis Delta—Distinguishing Cirrhosis Prevalence From Portal Hypertension Severity. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.71030
BibTeX
@article{Weng2026,
author = {Weng, Dandan and Zhang, Pingping},
title = {Letter: The Q425R Variant in Chronic Hepatitis Delta—Distinguishing Cirrhosis Prevalence From Portal Hypertension Severity},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.71030}
}
EUVIMED